Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | IL6ST | P40189 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15161868 | 0.91 | CA1 (0.48) | CA1CA9 | |
| SCHEMBL15161800 | 0.90 | CA1 (0.50) | CA1CA9ALDH1A1 | |
| SCHEMBL3959055 | 0.87 | CA1 (0.47) | CA1CA9 | |
| Valeric Acid SCHEMBL27694073 | 0.85 | CA1 (0.52) | CA1CA9ALDH1A1LTB4RLTB4R2 | |
| Butyrolactone SCHEMBL28503593 | 0.85 | CA1 (0.42) | CA1CA9ALDH1A1 | |
| SCHEMBL18130362 | 0.84 | CA1 (0.50) | CA1CA9ALDH1A1 | |
| SCHEMBL31346638 | 0.82 | CA1 (0.44) | CA1CA9ALDH1A1 | |
| SCHEMBL8999588 | 0.81 | CA1 (0.41) | CA1CA9 | |
| Hexanoate SCHEMBL28426223 | 0.81 | AKR1B1 (0.50) | CA1CA9CYP1A2ALDH1A1LTB4R | |
| Tetrahydrofuran SCHEMBL29101951 | 0.80 | CES1 (0.38) | CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063585-A1 | MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | HEMOTEQ AG (DE) | 2010-03-11 | — | — | US | claimed |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | HEMOTEQ AG (DE) | 2005-06-16 | — | — | US | claimed |
| CN-102458497-B | Catheter balloon coated with shellac and paclitaxel | 生物传感器欧洲股份公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20140099354-A1 | BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS | Dietz, Ulrich (DE) | 2014-04-10 | — | — | US | disclosed |
| US-8623097-B2 | Implant system having a functional implant composed of degradable metal material | BIOTRONIK VI PATENT AG (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20130005758-A1 | MANUFACTURE, METHOD AND USE OF DRUG-ELUTING MEDICAL DEVICES FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | HEMOTEQ AG. | 2013-01-03 | — | — | US | disclosed |
| CN-1889974-B | Oligopeptides as coating material for medical products | HEMOTEQ GMBH | 2012-08-29 | — | — | CN | disclosed |
| US-20100063585-A1 | MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | HEMOTEQ AG (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100010640-A1 | IMPLANT SYSTEM HAVING A FUNCTIONAL IMPLANT COMPOSED OF DEGRADABLE METAL MATERIAL | BIOTRONIK VI PATENT AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | HEMOTEQ AG (DE) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063585-A1 | MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | RICTOR, VEGFA, RPTOR | CA1 3500/4885CA9 1688/4885NAAA 1680/4885 |
| US-20140099354-A1 | BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS | PHOSPHO1, PTDSS1, LIPG | CA1 989/4885CA9 1217/4885NAAA 71/4885 |
| US-20130005758-A1 | MANUFACTURE, METHOD AND USE OF DRUG-ELUTING MEDICAL DEVICES FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN | RICTOR, VEGFA, RPTOR | CA1 4199/4885CA9 1348/4885NAAA 3618/4885 |
| US-20050129731-A1 | Biocompatible, biostable coating of medical surfaces | MSR1, CD44, PIGS | CA1 1897/4885CA9 1138/4885NAAA 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.